What was known before {#section21-2054358119880188}
=====================

Acute kidney injury is common in the pediatric intensive care unit. Acute kidney injury in adults is associated with increased risk of long-term chronic kidney disease, but little is known about this association in children.

What this adds {#section22-2054358119880188}
==============

We designed an algorithm for defining pediatric chronic kidney disease using administrative health data. We then used this to evaluate the association between acute kidney injury and 5-year chronic kidney disease in a large pediatric cohort.

Introduction {#section23-2054358119880188}
============

Acute kidney injury (AKI) is defined as an abrupt onset of kidney dysfunction and is common in the pediatric intensive care unit (ICU). Children who develop AKI in the pediatric ICU are at increased risk of mortality and morbidity.^[@bibr1-2054358119880188][@bibr2-2054358119880188][@bibr3-2054358119880188]-[@bibr4-2054358119880188]^ In adults, AKI increases risk for long-term incident chronic kidney disease (CKD).^[@bibr5-2054358119880188][@bibr6-2054358119880188]-[@bibr7-2054358119880188]^ In both adults and children, CKD is defined as the presence of markers of kidney injury (eg, albuminuria; known renal malformation) or decreased kidney function for more than 3 months.^[@bibr8-2054358119880188]^ In the general population, the prevalence of CKD is extremely low in children; however, pediatric studies have reported higher than expected long-term CKD prevalence after AKI. Most studies have lacked non-AKI comparison groups^[@bibr9-2054358119880188]^ or have not evaluated pediatric ICU patients specifically.^[@bibr10-2054358119880188],[@bibr11-2054358119880188]^ Thus, the extent to which children with AKI should be followed for long-term CKD development remains unclear.

The objectives of this study were to develop a pediatric CKD definition using administrative data and assess it for face validity. We also used this administrative data definition to evaluate if AKI is associated with a diagnosis of CKD 5 years after hospital discharge. We hypothesized that children with AKI in the ICU are at increased risk of CKD compared with patients with no AKI.

Methods {#section24-2054358119880188}
=======

Design, Setting, and Patients {#section25-2054358119880188}
-----------------------------

We performed a retrospective cohort study of children (≤18 years old) admitted to two pediatric ICUs in Montreal, Canada between January 1, 2003 and March 31, 2005. We a priori excluded patients with preadmission end-stage renal disease or if this diagnosis was made during index admission, and patients with no health care number. We included the first hospitalization per patient during the study period. We excluded patients who could not be linked to provincial data, did not survive hospitalization, or had preexisting renal or urinary tract abnormalities (by chart review), or a diagnostic code for CKD or a prescription of CKD-specific medication 12 months before admission (per administrative data). We also excluded patients with low baseline estimated glomerular filtration rate (eGFR) (≥1 month old: eGFR \< 35 mL/min/1.73m^2^ using the CKD in Children \[CKiD\] formula; \<1 month old: eGFR \<2 standard deviations from mean normative value, because glomerular filtration rate \[GFR\] = 35 mL/min/1.73m^2^ is within 2 standard divisions of the mean normative value; see [Figure 1](#fig1-2054358119880188){ref-type="fig"}).^[@bibr12-2054358119880188],[@bibr13-2054358119880188]^ Approvals from institutional research ethics boards and the Commission d'accès à l'information du Québec (CAI; provincial ethics body) were obtained. Requirement for patient consent was waived.

![Study flow and patient selection criteria leading to the analysis population.\
*Note.* PICU = pediatric intensive care unit; RAMQ = Régie de l'assurance maladie du Québec; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate.](10.1177_2054358119880188-fig1){#fig1-2054358119880188}

Data Collection and Sources {#section26-2054358119880188}
---------------------------

Index hospitalization data were collected by retrospective chart review (described previously).^[@bibr4-2054358119880188],[@bibr14-2054358119880188]^ Variables collected included primary ICU admission diagnosis, treatment details, and illness severity measures ([Supplemental Table 1](https://journals.sagepub.com/doi/suppl/10.1177/2054358119880188)). Chart data were merged with the Quebec Vital Statistics Registry and administrative health databases (Régie de l'assurance maladie du Québec \[RAMQ\] and MED-ECHO) from which data from January 1, 2002 to March 31, 2010 (12 months before the first hospitalization and 5 years after the last hospital admission) were available. The RAMQ database contains (1) a demographic database; (2) a medical services database (including outpatient services date and International Classification of Diseases, Ninth Revision \[ICD-9\] and International Classification of Diseases, Tenth Revision \[ICD-10\] diagnostic codes); and (3) a outpatient prescription database for patients with provincial medication insurance. The MED-ECHO database contains acute care hospitalization data including admission and discharge dates, primary diagnosis, procedures, and up to 15 secondary diagnoses (ICD-9/10 codes). The codes from the index admission were used to calculate the Pediatric Medical Complexity Algorithm, which classifies children with chronic disease according to medical complexity.^[@bibr15-2054358119880188]^ Emigration could not be determined with certainty; however, \<0.5% of the Quebec population emigrated per year during this study period.^[@bibr16-2054358119880188]^

Primary Exposure: AKI {#section27-2054358119880188}
---------------------

Acute kidney injury was defined using serum creatinine (SCr) and urine output criteria, based on the Kidney Disease: Improving Global Outcomes (KDIGO) definition.^[@bibr17-2054358119880188],[@bibr18-2054358119880188]^ AKI was classified as stage 1 (SCr rise ≥ 1.5-1.9 times baseline in 7 days or ≥26.5 µmol/L within 48 hours or urine output \< 0.5 mL/kg/h for 8 hours), stage 2 (SCr rise ≥ 2.0-2.9 times baseline or urine output \< 0.5 mL/kg/h for 16 hours), and stage 3 (SCr rise ≥ 3.0 times baseline, SCr ≥ 353.6 µmol/L, dialysis treatment for AKI, or eGFR \< 35 mL/min/1.73m^2^ \[if \>3 months old\] or urine output \< 0.3 mL/kg/h for 24 hours, or anuric for 12 hours). Baseline SCr was the lowest measurement 3 months before admission. If this was unavailable, baseline was estimated by back-calculation using a previously validated method.^[@bibr19-2054358119880188]^ The maximum AKI stage defined by SCr or urine output criteria was used to classify severity. To maximize sample size and reduce bias, patients without SCr or urine output measurements were classified as non-AKI, as previously performed.^[@bibr20-2054358119880188]^

Outcome: CKD {#section28-2054358119880188}
------------

A detailed literature review focused on administrative data--defined CKD was performed. A total of 11 original articles and 1 review article containing CKD algorithms using ICD-9/10 codes were evaluated.^[@bibr21-2054358119880188][@bibr22-2054358119880188][@bibr23-2054358119880188][@bibr24-2054358119880188][@bibr25-2054358119880188][@bibr26-2054358119880188][@bibr27-2054358119880188][@bibr28-2054358119880188][@bibr29-2054358119880188][@bibr30-2054358119880188][@bibr31-2054358119880188][@bibr32-2054358119880188]-[@bibr33-2054358119880188]^ A list of codes used to define CKD was created, excluding codes that were not applicable to children or too general. Remaining codes were ranked from 1 to 3, where 1 indicated the most specific codes based on validation studies and coauthor opinions (adult/pediatric nephrologists, pharmaco-epidemiologist, statistician).^[@bibr21-2054358119880188],[@bibr25-2054358119880188],[@bibr26-2054358119880188],[@bibr30-2054358119880188],[@bibr31-2054358119880188],[@bibr33-2054358119880188]^ We designed two algorithms for initial evaluation, including one stricter definition and one broader definition. The stricter algorithm only includes codes consistent with the KDIGO CKD criteria (CKD, proteinuria, outpatient dialysis); the broader algorithm includes CKD codes as well as other codes associated with CKD from the literature review ([Supplemental Table 2](https://journals.sagepub.com/doi/suppl/10.1177/2054358119880188)). These diagnostic codes were combined with CKD-specific medications, primarily selected by expert opinion (see [Table 1](#table1-2054358119880188){ref-type="table"}).^[@bibr27-2054358119880188]^

###### 

CKD Definition: One or More Diagnostic Codes, OR CKD Outpatient Medication Prescription.

![](10.1177_2054358119880188-table1)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CKD algorithm                                                                                                                                                                                                                      
  ---------------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------
  Dialysis related procedural codes                                                                                                                                                                                                  

  CKD                                                                          585                                                                 N18.x                                                                             Erythropoietin\
                                                                                                                                                                                                                                     Activated vitamin D\
                                                                                                                                                                                                                                     Potassium-binding agents\
                                                                                                                                                                                                                                     Phosphate-binding agents

  Unspecified renal failure                                                    586                                                                 N19                                                                               

  Proteinuria                                                                  791.0                                                               R80                                                                               

  Kidney transplant                                                            V42.0, 996.8, 590.8                                                 Z94.0, T86.100, T86.101, N16.5                                                    

  Transplant related procedural codes                                                                                                                                                                                                

  Dialysis related procedural codes                                            5127, 5142, 5129, 660                                               1KY76LA, 1KY80LA, 1KG76MZXXA, 1KG76MZXXN, 1SY55LAFT                               

  Transplant related procedural codes                                          6751, 6759, 6483                                                    1PC83LA, 1PC85LAXXJ, 1PC85LAXXK, 1OK85TNXXK, 1OK85XTXXK, 1OK85XUXXK, 1OK85XVXXK   

  Outpatient diagnostic (ICD-9 or ICD-10)/procedural codes (CCP or CCI) only                                                                                                                                                         

  Dialysis related procedural codes                                                                                                                                                                                                  

  Dialysis related diagnostic codes                                            V45.1, V53.9, V56.0, V56.8, 996.1, E87.02, E87.12, E87.22, E87.91   Z99.2, Z49.0, Z49.1, Z49.2, T82.4, Y60.2, Y61.2, Y62.2, Y84.1                     

  Transplant related procedural codes                                                                                                                                                                                                

  Dialysis related procedural codes                                            6698, 5195, 0789, 6693                                              1PZ21HPD4, 1PZ21HQBR, 7SC59QD, 1OT53DATS, 1OT53HATS, 1OT53LATS                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* CKD = chronic kidney disease; ICD-9/10 = International Classification of Diseases, Ninth Revision; ICD-10 = International Classification of Diseases, Tenth Revision; CCP = Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedure; CCI = Canadian Classification of Health Interventions.

In the province of Quebec, administrative health care data used ICD-9 until the fiscal year of 2006; thereafter, ICD-10 coding was used.

Three different combinations of codes were evaluated (diagnostic codes alone \[1\], diagnosis AND \[2\]/OR medication \[3\]). These combinations were made with the stricter and broader definition diagnostic codes separately. A preliminary univariable analysis comparing CKD between AKI and non-AKI patients using all algorithms was performed: All algorithms showed a statistically significant difference (not shown).

[Table 1](#table1-2054358119880188){ref-type="table"} shows the final CKD algorithm (expanded; [Supplemental Table 3](https://journals.sagepub.com/doi/suppl/10.1177/2054358119880188)). We selected the stricter definition codes to be confident of AKI-outcome associations. The diagnostic and procedural codes were divided into two categories: (1) inpatient or outpatient codes and (2) outpatient codes only. A patient was defined as having CKD if he or she had ≥1 CKD diagnostic codes and/or ≥1 prescription for CKD-specific medication 5 years post-hospital discharge. This allowed the inclusion of patients uninsured by provincial medication coverage (\~70%).

Analysis {#section29-2054358119880188}
--------

Associations between baseline patient and treatment characteristics with AKI and CKD were evaluated using appropriate univariable analyses. Associations with AKI and CKD individually, as well as CKD stratified by AKI (yes/no), were performed. All analyses were planned a priori and conducted using SAS statistical software, release 9.2 (SAS Institute Inc, Cary, NC, USA). Reporting was prepared in accordance to guidelines.^[@bibr34-2054358119880188]^

Cumulative incidence curves were plotted by no vs stage 1 vs stage 2-3 AKI. Multivariable Cox regression was performed to evaluate the association between AKI and 5-year CKD. Variables were included in the multivariable analysis if they were associated with the exposure (AKI) and the outcome (CKD) at the *P* \< .01 level.

The characteristics between the patients without an SCr or urine output measurement during ICU admission and those with measurements but with no AKI during ICU admission were compared. Sensitivity analysis was performed, excluding patients without SCr or urine output measurements. To ensure that we were not including patients with a CKD diagnosis prior to admission (but not recorded in the data), or those with temporary post-AKI dialysis, in the outcomes, cumulative incidence curves excluding CKD diagnoses made 90 days post-hospital discharge were made.

We also compared nephrology specialist visit follow-up after hospital discharge between patients with vs without AKI and patients with vs without CKD diagnosis. After detailed group discussion, we used the presence of ≥2 nephrology visits within 16 months to indicate the presence of regular nephrology follow-up.

Results {#section30-2054358119880188}
=======

Patient Characteristics {#section31-2054358119880188}
-----------------------

A total of 2235 patients were included (56% male), with the median (interquartile range \[IQR\]) age of 3.7 (10.4) years and the median (IQR) follow-up of 5.0 (0) years; of these, 464 (21%) developed AKI during ICU admission. A total of 43 (2%) patients had algorithm-defined CKD diagnosis 5 years post-hospital discharge (see [Table 1](#table1-2054358119880188){ref-type="table"}; 39 diagnostic codes only, 2 medications only, 2 both diagnostic codes and medications). Few children fulfilled the medication criteria; however, only \~30% had medication coverage through provincial insurance plans. Chronic kidney disease diagnosis was ascertained a median (IQR) of 1.1 (2.4) years post-discharge. During follow-up, 95 (4%) patients died.

[Table 2](#table2-2054358119880188){ref-type="table"} shows univariable associations between baseline characteristics with AKI and 5-year CKD. Variables associated with AKI and 5-year CKD with *P* \< .01 included chronic illness by the pediatric medical complexity algorithm^[@bibr15-2054358119880188]^ and nephrotoxic antibiotics use in the ICU. Patients with AKI and CKD had longer ICU and hospital stays (see [Table 2](#table2-2054358119880188){ref-type="table"}). Among the patients with AKI in the pediatric ICU, those who had a diagnosis of CKD compared with those without a CKD diagnosis had a higher prevalence of admission diagnosis under the category of gastrointestinal or oncologic, nephrotoxic antibiotics, and had longer hospital stay ([Supplemental Table 4](https://journals.sagepub.com/doi/suppl/10.1177/2054358119880188)).

###### 

Univariable Analysis of Patient and Pediatric ICU Characteristics by AKI and by 5-Year CKD Diagnosis.

![](10.1177_2054358119880188-table2)

  Variables                                                                                    No AKI (N = 1771)   AKI (N = 464)                                                        No CKD (N = 2192)   CKD (N = 43)
  -------------------------------------------------------------------------------------------- ------------------- -------------------------------------------------------------------- ------------------- ------------------------------------------------------------------
  Patient characteristics                                                                                                                                                                                   
   ICU admission age, years                                                                    3.7 (10.3)          3.6 (10.6)                                                           3.6 (10.4)          4.7 (11.4)
   Female sex                                                                                  787 (44%)           212 (46%)                                                            966 (44%)           28 (65%)[\*](#table-fn7-2054358119880188){ref-type="table-fn"}
   Center 2                                                                                    988 (56%)           310 (67%)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}    1271 (58%)          27 (63%)
   ICU diagnosis                                                                                                                                                                                            
    Cardiac surgery                                                                            163 (9%)            167 (36%)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}    323 (15%)           7 (16%)
    Cardiac (nonsurgical)                                                                      100 (6%)            27 (6%)                                                              123 (6%)            4 (9%)
    Trauma                                                                                     180 (10%)           34 (7%)                                                              213 (10%)           1 (2%)
    Infection (nonbronchiolitis)                                                               298 (17%)           72 (16%)                                                             362 (17%)           8 (19%)
    Neurologic/neurosurgical                                                                   243 (14%)           38 (8%)[\*](#table-fn7-2054358119880188){ref-type="table-fn"}        277 (13%)           4 (9%)
    Gastrointestinal^[a](#table-fn4-2054358119880188){ref-type="table-fn"}^                    46 (3%)             22 (5%)[\*](#table-fn7-2054358119880188){ref-type="table-fn"}        61 (3%)             7 (16%)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}
    Oncologic                                                                                  43 (2%)             7 (2%)                                                               47 (2%)             3 (7%)
    Respiratory                                                                                186 (11%)           28 (6%)[\*](#table-fn7-2054358119880188){ref-type="table-fn"}        212 (10%)           2 (5%)
    Diabetes                                                                                   39 (2%)             16 (3%)                                                              54 (2%)             1 (2%)
    Other^[b](#table-fn5-2054358119880188){ref-type="table-fn"}^                               473 (27%)           53 (11%)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}     520 (24%)           6 (14%)
   Postoperative (noncardiac)                                                                  580 (33%)           83 (18%)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}     654 (30%)           9 (21%)
   PRISM death rate                                                                            1.9 (3.7)           4.9 (13.9)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}   2.2 (4.7)           2.0 (7.8)
   Pediatric Medical Complexity Algorithm                                                                          [\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}                                 [\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}
    No chronic disease                                                                         333 (19%)           52 (11%)                                                             383 (17%)           2 (5%)
    Noncomplex chronic disease                                                                 436 (25%)           75 (16%)                                                             509 (23%)           2 (5%)
    Complex chronic disease                                                                    1002 (57%)          337 (73%)                                                            1300 (60%)          39 (91%)
  ICU characteristics and outcomes                                                                                                                                                                          
   Nephrotoxic antibiotics in the ICU^[c](#table-fn6-2054358119880188){ref-type="table-fn"}^   304 (17%)           156 (34%)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}    439 (20%)           21 (49%)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}
   NSAIDs                                                                                      178 (10%)           90 (19%)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}     263 (12%)           5 (12%)
   Vasopressors used (yes/no)                                                                  178 (10%)           215 (46%)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}    382 (17%)           11 (26%)
   Steroids used (yes/no)                                                                      444 (25%)           142 (31%)[\*](#table-fn7-2054358119880188){ref-type="table-fn"}      570 (26%)           16 (37%)
   Mechanically ventilated (yes/no)                                                            697 (39%)           327 (70%)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}    1007 (46%)          17 (40%)
   Length of mechanical ventilation, days                                                      0 (2)               2 (6)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}        0 (2)               0 (3)
   ICU length of stay, days                                                                    1.1 (1.9)           3.7 (7.1)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}    1.5 (2.7)           2.5 (5.6)[\*](#table-fn7-2054358119880188){ref-type="table-fn"}
   Hospital length of stay                                                                     7 (9)               13 (18)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}      8 (11)              19 (40)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}
  Kidney related                                                                                                                                                                                            
   Baseline eGFR                                                                               120 (36)            120 (49)                                                             120 (36)            120 (49)
   Renal replacement therapy in ICU                                                            0                   4 (0.9%)[\*\*](#table-fn7-2054358119880188){ref-type="table-fn"}     3 (0.1%)            1 (2%)

*Note.* Continuous variables are presented as median (IQR) and categorical variables are presented as number (percentage). Associations between continuous variables were determined using Student *t* test or Kruskal-Wallis test depending on the distribution. Categorical variables were evaluated using chi-square test or Fisher exact test. ICU = intensive care unit; AKI = acute kidney injury defined using serum creatinine and urine output; CKD = chronic kidney disease; PRISM = Pediatric Risk of Mortality; NSAIDs = nonsteroidal anti-inflammatory drugs; eGFR = estimated glomerular filtration rate; IQR = interquartile range.

Includes the liver, stomach, pancreas, and intestine.

Includes hematologic (nononcologic), inborn error of metabolism and metabolic (noninborn error of metabolism), immunologic, intoxication, burn, orthopedic, otolaryngologic, endocrinologic (nondiabetes), and bronchiolitis.

Includes aminoglycosides, acyclovir/ganciclovir, amphotericin, and vancomycin.

*P* \< .05. \*\**P* \< .001.

AKI-CKD Association {#section32-2054358119880188}
-------------------

[Figure 2](#fig2-2054358119880188){ref-type="fig"} shows the cumulative incidence of CKD by AKI strata. Patients with stage 2-3 AKI had higher incidence of CKD diagnosis, especially 1 year after discharge. In univariable and multivariable analyses, AKI was associated with CKD 5 years post-discharge (see [Table 3](#table3-2054358119880188){ref-type="table"}). Patients with either stage 1 or stage 2-3 AKI had more than 2 times higher adjusted risk of CKD diagnosis 5 years post-discharge relative to non-AKI patients (see [Table 3](#table3-2054358119880188){ref-type="table"}).

![Cumulative incidence curves for CKD stratified by AKI severity.\
*Note.* The figure compares the incidence of a CKD diagnosis in patients with no AKI (solid line), stage 1 AKI (dashed line), and stage 2-3 AKI (dotted line). Time 0 is the date of hospital discharge. Log-rank test was used to compare groups. Incidence of a CKD diagnosis increases with the increasing severity of AKI. CKD = chronic kidney disease; AKI = acute kidney injury.](10.1177_2054358119880188-fig2){#fig2-2054358119880188}

###### 

Proportion of Patients With CKD and Univariable and Multivariable Cox Regression for Association Between AKI and 5-Year CKD.

![](10.1177_2054358119880188-table3)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Classification               CKD        *P* value   Univariable HR (95% CI)                                                  Multivariable HR (95% CI)^[a](#table-fn9-2054358119880188){ref-type="table-fn"}^
  ---------------------------- ---------- ----------- ------------------------------------------------------------------------ ----------------------------------------------------------------------------------
  No AKI (N = 1771)\           23 (1%)\   \<.001      1.00\                                                                    1.00\
  AKI (N = 464)                20 (4%)                3.4 (1.9-6.2)[\*\*](#table-fn10-2054358119880188){ref-type="table-fn"}   2.3 (1.3-4.3)[\*](#table-fn10-2054358119880188){ref-type="table-fn"}

  No AKI/stage 1 (N = 2077)\   34 (2%)\   \<.001      1.00\                                                                    1.00\
  Stage 2/3 (N = 158)          9 (6%)                 3.6 (1.7-7.6)[\*\*](#table-fn10-2054358119880188){ref-type="table-fn"}   2.1 (1.0-4.4)

  No AKI (N = 1771)\           23 (1%)\   \<.001      1.00\                                                                    1.00\
  Stage 1 (N = 306)\           11 (4%)\               2.8 (1.4-5.8)[\*](#table-fn10-2054358119880188){ref-type="table-fn"}\    2.2 (1.1-4.5)[\*](#table-fn10-2054358119880188){ref-type="table-fn"}\
  Stage 2/3 (N = 158)          9 (6%)                 4.6 (2.1-9.9)[\*\*](#table-fn10-2054358119880188){ref-type="table-fn"}   2.5 (1.1-5.7)[\*](#table-fn10-2054358119880188){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note*. CKD = chronic kidney disease; AKI = acute kidney injury; HR = hazard ratio; CI = confidence interval; ICU = intensive care unit.

Adjusted for Pediatric Medical Complexity Algorithm and nephrotoxic antibiotic use in the pediatric ICU.

*P* \< .05. \*\**P* \< .001.

Sensitivity Analyses {#section33-2054358119880188}
--------------------

Of all 2235 patients, 1833 had measured SCr and/or urine output in the ICU (852 had both; 45 only urine output; and 936 only SCr). The 402 patients without measurements had lower illness severity scores, were less likely to receive vasopressors and mechanical ventilation, had shorter ICU stays, higher baseline GFR, and slightly lower 5-year mortality (3% vs 5%, *P* = .05) vs known non-AKI patients ([Supplemental Table 5](https://journals.sagepub.com/doi/suppl/10.1177/2054358119880188)). When excluding patients without SCr or urine output measurements, AKI remained associated with CKD in adjusted analysis, with adjusted hazard ratio (95% confidence interval \[CI\]): 2.6 (1.3-5.0), *P* = .005 ([Supplemental Table 6](https://journals.sagepub.com/doi/suppl/10.1177/2054358119880188)).

After excluding patients diagnosed with CKD 90 days after discharge, the association of increasing risk of CKD diagnosis with increasing AKI severity remained significant ([Supplemental Figure 1](https://journals.sagepub.com/doi/suppl/10.1177/2054358119880188)).

In our cohort, out of the 2235 patients, 110 (5%) saw a nephrologist ≥2 times within 16 months during the 5 years of follow-up. Of patients with AKI, 36/464 (8%) saw a nephrologist ≥2 times within 16 months compared to 74/1771 (4%) non-AKI patients (*P* = .002). A higher proportion of patients with a CKD diagnosis had ≥2 nephrology visits within 16 months during the 5 years of follow-up (CKD: 19/43 \[44%\] vs non-CKD: 91/2192 \[4%\], *P* \< .001).

Discussion {#section34-2054358119880188}
==========

Using a proposed algorithm to define CKD in children, we found that pediatric ICU AKI is independently associated with increased risk of a CKD diagnosis 5 years post-hospital discharge.

Although the association between AKI and CKD is well characterized in adults, it is less well understood in children. Potential mechanisms for AKI to CKD progression include loss of renal mass causing hyperfiltration damage and cellular pathophysiological events leading to fibrosis.^[@bibr35-2054358119880188]^ Pediatric studies evaluating the AKI-CKD association have been limited by sample size, lack of non-AKI comparison groups, and inconsistent definitions, making it difficult to understand if these children are at risk.^[@bibr9-2054358119880188],[@bibr36-2054358119880188],[@bibr37-2054358119880188]^ A recent Danish population--based registry study found that pediatric cardiac surgery patients with AKI are at greater risk of CKD (based on eGFR measurements) 5 years post-discharge.^[@bibr10-2054358119880188]^ We found a lower incidence (2%); however, this is somewhat expected as the adult literature has demonstrated that using administrative data tends to *underestimate* CKD incidence, generally capturing more late--stage disease. Considering this and that the general pediatric population CKD prevalence is extremely low, our findings suggest that the pediatric ICU population is globally at higher risk for long-term CKD.^[@bibr38-2054358119880188],[@bibr39-2054358119880188]^ This patient population should be targeted for research to identify risk factors for CKD development and follow-up strategies to reduce CKD incidence, followed by an evaluation of the effects of such interventions.

Compared with the past pediatric AKI literature, our study is unique because it combines chart data to define our exposure with administrative data to define outcomes, allowing for a large sample size and multivariable analysis controlling for potential confounders. Our finding of an AKI-CKD association justifies the need for future research to validate this and other CKD algorithms. Adult studies evaluating the validity of administrative data--based CKD definitions have shown that these algorithms often have low sensitivity but high specificity (\>95%).^[@bibr21-2054358119880188],[@bibr26-2054358119880188],[@bibr30-2054358119880188],[@bibr40-2054358119880188]^ Our pediatric definition likely follows similar patterns. This lack in sensitivity is a limitation for all studies using administrative data.^[@bibr41-2054358119880188]^

Our CKD definition and methodology were designed to evaluate the face validity of using administrative data to evaluate long-term kidney outcomes in children. We did not validate the definition. Rather, we determined if CKD using administrative data was detectable in a pediatric population (as childhood CKD prevalence is low) and whether, in a pediatric ICU population, AKI showed evidence of association with long-term CKD, as observed in adults.^[@bibr5-2054358119880188][@bibr6-2054358119880188]-[@bibr7-2054358119880188]^ Despite the lack of validity evaluation (which would require population-level laboratory review), as described above, studies in adults show that CKD diagnosis using administrative data has high specificity.^[@bibr21-2054358119880188],[@bibr26-2054358119880188],[@bibr30-2054358119880188],[@bibr40-2054358119880188]^ If specificity of administrative data--defined CKD is lower than expected in children, the effect would most likely have been to reduce the magnitude of the AKI-CKD association. Moving forward, our study supports the large task involved in performing a validation study of this and other CKD algorithms to better interpret associations with different exposures, including AKI.

In secondary analyses, we evaluated if AKI or CKD were associated with nephrology follow-up. We did this for 3 reasons. First, we wanted to explore other measures in administrative data that may increase sensitivity for CKD diagnosis. Second, we sought to begin understanding the extent to which these patients are or are not being followed by nephrologists. Third, we wanted to evaluate for potential ascertainment bias; if patients with AKI diagnosis were more likely to be seen by a nephrologist after discharge, it follows that CKD diagnosis may be more common due to increased diagnostic testing (ie, ascertainment). Only 8% of patients with AKI saw a nephrologist ≥2 times within 16 months; this occurred twice more often than in non-AKI patients, suggesting that there may have been some ascertainment bias in our findings on AKI-CKD associations. Prospective studies with unbiased laboratory measurements should be conducted to validate our findings. The nephrology follow-up prevalence in our study also highlights that few AKI patients were followed by a nephrologist. There are no pediatric-specific international guidelines on how children with AKI should be followed. Future research should attempt to better understand AKI follow-up patterns and reasons for follow-up/non-follow-up and evaluate the impact of systematic AKI follow-up.

Our study had limitations. We only had access to administrative data 12 months before admission. It is possible that some patients had a CKD diagnosis before index admission which was not detected. We attempted to limit this by excluding patients with any indication of renal or urinary tract issues from chart review. Moreover, sensitivity analysis excluding patients diagnosed with CKD 90 days post-discharge showed a persistent association with severe AKI and CKD diagnosis. Given that a significant proportion of patients excluded were neonates at pediatric ICU admission for whom we did not have access to a health care number and could not match to the administrative health care data, our study may be biased toward nonneonates. However, given the unique risk factors for acute and chronic kidney injury in neonates, it is worthwhile in future research to evaluate long-term outcomes of AKI in this population. Only \~30% of our population had medications covered by the provincial drug plan, and therefore this aspect of the algorithm contributed little to our results. However, we included medications in our definition so future researchers with access to medication information can evaluate this algorithm. Although we controlled for the effects of multiple index admission variables, there are post-discharge variables (new treatments, diagnoses) that we could not account for. Future research should try to explore these additional potential risk factors further. A challenge present in all studies evaluating the association of AKI with later outcomes is that many of the risk factors or potential confounders that are traditionally adjusted for in analyses may be *causes* of AKI; thus, AKI would be on the causal pathway to CKD (eg, nephrotoxic medication or illness severity leads to AKI, followed by CKD). Future research should attempt to elucidate the extent to which different causes of AKI may independently contribute to CKD development. As noted above, we were not able to validate this algorithm with the data we had available; however, the goal of this study was to design and assess the face validity of a pediatric-specific CKD definition and to determine whether it is feasible to study pediatric CKD using administrative data. This population is from 2003 to 2005, with follow-up until 2010; this may limit the generalizability of this study, and it is possible that trends in follow-up or CKD detection could have changed. However, no guidelines on how children with AKI should be followed have been established. This research may not be generalizable to non-critically ill populations. We were unable to determine the impact of emigration on our associations. However, during the study period, Quebec population's yearly emigration was \<0.5% and there is little reason to suspect a difference between AKI and non-AKI patients.^[@bibr16-2054358119880188]^
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In conclusion, patients admitted to the pediatric ICU are at overall high risk for long-term CKD development. Patients with AKI are at increased risk of CKD diagnosis 5 years post-discharge compared with patients without AKI. Future research should validate the pediatric-specific CKD definition and focus on developing follow-up guidelines for children that are at higher risk of developing CKD after ICU admission. We propose that administrative health care data may provide a rich source from which to evaluate AKI's association with long-term renal outcomes and understand follow-up patterns and costs associated with pediatric AKI. We also believe that this study contributes to justification of the need to devote resources to perform large, prospective studies of long-term kidney outcomes in critically ill children with AKI.
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